Drug Trial Radar · NCT04684108
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
61
Actual
Start
Nov 4, 2021
Primary completion
Jun 30, 2024
Study completion Dec 30, 2026
Sponsor
- Lead sponsor
- Hangzhou Sumgen Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1a/1b Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG301 in Patients with Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
Conditions
- Relapsed or Refractory Multiple Myeloma
- Hematological Malignancy
Interventions
SG301Drug
Phase 1a will use an accelerated titration and 3+3 design with 9 dose cohorts: 0.005 mg/kg, 0.05 mg/kg,0.5 mg/kg, 1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, 12 mg/kg and 16 mg/kg by IV infusion. Accelerated titration (i.e., 1 patient each) will be applied to the first 3 cohorts.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse EventsTime frame: Through study completion, an average of one year
- MTD/MAD/ RP2DTime frame: Through study completion, an average of one year
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China
Affiliated Beijing Chaoyang Hospital of Capital Medical University
Beijing, Beijing Municipality, China
Beijing Jishuitan Hostipal
Beijing, Beijing Municipality, China
Shenzhen Second People's Hospital
Shenzhen, Guangzhou, China
The Fourth Affiliated Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Wuhan University Central South Hospital
Wuhan, Hubei, China
Xiangyang Central Hospital
Xiangyang, Hubei, China
Wuxi Central Hospital
Wuxi, Jiangsu, China
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China
Shengjing Hospital Affiliated to China Medical University
Shenyang, Liaoning, China
Qilu Hospital of Shandong University
Jinan, Shandong, China
Shanxi Norman Bethune Hospital
Taiyuan, Shanxi, China
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.